Genetics of common disease and diagnostics

Through its CLIA-registered testing facility deCODE currently offers DNA-based tests for gauging genetic risk of Myocardial Infarction (MI), Type 2 Diabetes (T2D), Atrial Fibrillation (AF), Glaucoma (Glaucoma) and Prostate Cancer (ProstateCancer):

deCODE T2 - for gauging risk of Type 2 Diabetes
deCODE T2
Download Order FormsdeCODE T2™ is aimed at helping physicians assess the genetic risk of type 2 diabetes in their patients, and to enable lifestyle and therapeutic strategies that may reduce the risk of developing diabetes in the future.
Read more >>

deCODE AF - for gauging risk of Atrial Fibrillation
deCODE AF
Download Order Forms deCODE AF™ offers a novel means of  identifying those who may benefit from outpatient cardiac monitoring after leaving the hospital.
Read more >>

deCODE MI - for gauging risk of MI
deCODE MI
Download  Order Forms deCODE MI™ detects previously unrecognized genetic risk of MI that appears to be in addition to welll known risk factors such as elevated cholesterol and hypertension. The test may be positive even in patients of families without history of heart attacks.
Read more >>

deCODE GL- for gauging risk of Glaucoma
deCODE GL
Download  Order Forms deCODE Glaucoma™ is a reference laboratory DNA test for assessing an inherited risk factor for exfoliation glaucoma. The deCODE Glaucoma™ test detects versions of SNPs (single nucleotide polymorphism) – single letter variations in the sequence of the genome – in a specific gene that deCODE has linked to increased risk of one of the more common types of glaucoma, exfoliation type glaucoma.
Read more >>

deCODE PrCa - for gauging risk of Prostate Cancer
deCODE PrCa
Download  Order Forms deCODE ProstateCancer™ is a reference laboratory DNA test for assessing an inherited risk factor for Prostate Cancer.
Read more >>

deCODE BreastCancer - for gauging risk of Breast Cancer
deCODE BreastCancer
Download  Order Forms deCODE BreastCancer is a reference laboratory DNA test for assessing individual risk of the common forms of breast cancer. the common forms of the disease account for approximately 95% of all breast cancers, and the test detects versions of seven SNPs that deCODE and others have linked to risk of breast cancer in studies involving some 100,000 patients and controls from many populations.
Read more >>


About deCODE genetics
deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer.
Read more >>